

# The influence of supplementary regional infiltration anesthesia with ropivacaine on postoperative pain, nausea and vomiting in patients undergoing mamma surgery under general anesthesia

Published: 09-06-2008

Last updated: 11-05-2024

To investigate that in mamma surgery, regional infiltration with ropivacaine 0,75% added to general anaesthesia causes less postoperative pain, nausea and vomiting compared to general anaesthesia alone.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Breast neoplasms malignant and unspecified (incl nipple)
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON35556

### Source

ToetsingOnline

### Brief title

SUPplementary REgional anesthesia in MAMma surgery (SUPREMA trial)

### Condition

- Breast neoplasms malignant and unspecified (incl nipple)
- Breast disorders
- Breast therapeutic procedures

### Synonym

nausea and vomiting, pain

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Reinier de Graaf Groep

**Source(s) of monetary or material Support:** Astra Zeneca, Er worden 100 flacons Naropin gratis beschikbaar gesteld door de fabrikant (idem in vraag G2). Mogelijk zal er een beroep gedaan worden op het subsidiefonds van de Reinier de Graaf Groep.

## Intervention

**Keyword:** anaesthesia, breast, infiltration, regional

## Outcome measures

### Primary outcome

postoperative vomiting in the first 24 hours

### Secondary outcome

Postoperative nausea 4,8 and 24 hours after start of surgery (VAS score 0-10)

Postoperative pain 4,8 and 24 hours after start of surgery (VAS score 0-10)

Need for postoperative opiates (frequency and total dose in first 24 hours)

Need for anti-emetics (frequency and total dose in first 24 hours)

## Study description

### Background summary

The incidence of postoperative nausea and vomiting (PONV) varies from 20 to 80% in patients undergoing mamma surgery. PONV are strongly related to postoperative pain.

PONV are also well known side effects of opioids. Appropriate pain management during and after surgery without, or with a lower dose of opioids, may decrease the incidence of PONV. Earlier studies with different surgical operations showed that combining general anesthesia with regional infiltration anesthesia with a long acting local anesthetic provided superior and prolonged analgesia, compared with general anesthesia alone.

Therefore, regional infiltration anesthesia of the mamma with a long acting local anesthetic could provide better analgesia in mamma surgery under general

anesthesia compared to the same surgery under general anesthesia alone. This may lead to decreased incidence of PONV and decreased postoperative use of opiates and anti-emetics. Ropivacaine is chosen as a long acting local anesthetic because of its superior toxicological profile compared to bupivacaine.

## **Study objective**

To investigate that in mamma surgery, regional infiltration with ropivacaine 0,75% added to general anaesthesia causes less postoperative pain, nausea and vomiting compared to general anaesthesia alone.

## **Study design**

doubleblind placebo controlled randomized intervention study

## **Intervention**

Regional infiltration anesthesia of the ipsilateral breast with ropivacaine 0,75% (maximum volume 0,47 ml/kg) or placebo (a comparable volume of NaCl 0,9%). The regional infiltration consists of deep subcutaneous infiltration parallel to the clavicle, in the ipsilateral parasternal line and in a line parallel to and 0-1 cm posterior of the ipsilateral anterior axillary line. The infiltration trajects are from medial to lateral alongside the clavicle and from caudal to cranial at the trunk.

## **Study burden and risks**

The burden associated with participating consists of three subcutaneous injections with a total maximum volume of 0,47 ml/kg (with a maximum dose of 300 mg) of ropivacaine 0,75% or the same amount of NaCl 0,9%. Injections will be given under general anesthesia (which is already part of operating procedure).

Participation in this study includes side effects of infiltration anesthesia: inadvertent intravascular injection, bleeding in the infiltration traject and ipsilateral pneumothorax or numbness in the ipsilateral arm, due to brachial plexus involvement. Side effects of ropivacaine are mainly caused by systemic administration and include convulsions, hypotension and nausea. Hypotension and nausea are frequently seen with operating procedures and it is impossible to distinguish them as side effects due to the clinical situation from side effects caused by the drug or field block.

The risk of these side effects can be minimized by careful injection and therefore thorough training of the anesthesiologists participating in the study will be performed .

## Contacts

### Public

Reinier de Graaf Groep

Reinier de Graafweg 7  
2625 AD Delft  
NL

### Scientific

Reinier de Graaf Groep

Reinier de Graafweg 7  
2625 AD Delft  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

women

one-sided breast conserving surgery with or without sentinel node biopsy

age 18-80 yr

### Exclusion criteria

known allergy to amide type local anesthetics

severe liver failure

weight >120 kg

double-sided breast surgery

infections in the infiltration region

breast conserving surgery combined with plastic surgery  
pregnancy/lactation  
use of opiates  
use of anti-emetics

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Prevention

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	10-10-2008
Enrollment:	150
Type:	Actual

### Medical products/devices used

Product type:	Medicine
Brand name:	Naropin
Generic name:	ropivacaine
Registration:	Yes - NL intended use

## Ethics review

Approved WMO	
Date:	09-06-2008
Application type:	First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)  
metc-ldd@lumc.nl

Approved WMO  
Date: 31-07-2008  
Application type: First submission  
Review commission: METC Leiden-Den Haag-Delft (Leiden)  
metc-ldd@lumc.nl

Approved WMO  
Date: 25-03-2010  
Application type: Amendment  
Review commission: METC Leiden-Den Haag-Delft (Leiden)  
metc-ldd@lumc.nl

Approved WMO  
Date: 07-04-2010  
Application type: Amendment  
Review commission: METC Leiden-Den Haag-Delft (Leiden)  
metc-ldd@lumc.nl

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

**Register**

Other

EudraCT

CCMO

**ID**

1687

EUCTR2008-003161-89-NL

NL16755.098.08